On June 6, 2025, Axsome Therapeutics held its Annual Meeting, where shareholders elected a director, approved the 2025 Long-Term Incentive Plan, ratified Deloitte & Touche LLP as auditors, and approved executive compensation with significant support. Approximately 84% of shares were represented in the vote.